September 01, 2014 10:07 PM ET

Pharmaceuticals

Company Overview of Alba Therapeutics Corporation

Company Overview

Alba Therapeutics Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases. It offers a technology platform based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with applications in celiac disease, Crohn's disease, asthma/COPD, and acute lung injury. The company also provides solutions for various therapeutic areas, such as immune-based disorders, gastrointestinal diseases, metabolic diseases, pulmonary diseases, renal disease states, celiac diseases, inflammatory bowel di...

650 South Exeter Street

10th Floor

Suite 1040

Baltimore, MD 21202

United States

Founded in 2004

Phone:

410-864-3590

Fax:

410-319-0834

Key Executives for Alba Therapeutics Corporation

Chief Executive Officer
Co-Chairman
Age: 63
Chief Medical Officer
Head of Quality Control
Head of Chemistry
Compensation as of Fiscal Year 2014.

Alba Therapeutics Corporation Key Developments

Alba Therapeutics Corporation Announces Positive Results of Phase IIb Trial in Celiac Disease

Alba Therapeutics Corporation announced the positive results of their Phase IIb trial evaluating its investigational product, larazotide acetate, a tight junction regulator, intended for the treatment of patients with celiac disease (CeD). The study met its primary endpoint and, based on these results, Alba has initiated planning for Phase III clinical trials for the definitive assessment of the oral peptide's efficacy and safety. The final data will be submitted for publication in the near future. The double-blind, placebo-controlled study evaluated the efficacy and safety of larazotide acetate in the treatment of 342 patients with CeD who had persistent symptoms despite being on a gluten-free diet. This is the seventh study in a broad clinical trial program for larazotide acetate that, to date, has included 828 patients with CeD. Larazotide acetate has been granted 'Fast Track' designation from the FDA.

Alba Therapeutics Corporation Appoints Wendy Perrow as Chief Executive Officer

Alba Therapeutics Corporation announced the appointment of Wendy Perrow as its Chief Executive Officer (CEO). Her responsibilities include managing the company's business, clinical, financial, licensing, and corporate development efforts. Ms. Perrow previously served as President and COO and she has been a member of Alba's executive management team since 2008. Prior to joining Alba, Ms. Perrow held senior executive marketing positions with private and public pharmaceutical companies.

Similar Private Companies By Industry

Company Name Region
GeNO LLC United States
Seaside Therapeutics, LLC United States
Theramedix, Inc. United States
Sun Pharmaceutical Industries, Inc. United States
DaVinci Laboratories of Vermont United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Alba Therapeutics Corporation, please visit www.albatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.